ERBB2 and breast carcinoma: FGFR1 amplification was not significantly associated with any clinicopathologic features of breast cancer, but p53 overexpression and HER2 amplification tended to be elevated in tumors with FGFR1 amplification (p=0.089, p=0.085, respectively; Supplementary Table 3).